Truist Financial Trims Cytokinetics (NASDAQ:CYTK) Target Price to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective lowered by Truist Financial from $86.00 to $70.00 in a research report released on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on CYTK. JMP Securities cut their price […]

Related Keywords

,Fady Ibraham Malik ,Johnt Henderson ,Raymond James ,Cytokinetics Incorporated ,Bessemer Group Inc ,Cytokinetics Company Profile ,Fifth Third Bancorp ,Barclays ,Securities Exchange Commission ,Third Bancorp ,Entrypoint Capital ,Sage Rhino Capital ,Free Report ,Truist Financial ,Moderate Buy ,Stock Down ,Get Free Report ,Director John ,Exchange Commission ,Ibraham Malik ,Point Capital ,Cytokinetics Daily ,